ERBB2 and neoplasm: A multicenter Turkish trial MF07-01 showed a statistically significant improvement in surgery arm in 5-year follow-up, especially in patients with ER/PR (+) or HER2(−) tumor, solitary bone metastasis or younger age (<55 years old) (38).